text:
School of Music and The Cleveland Orchestra Partner for 45th Annual Kent/Blossom Music Festival
The Kent/Blossom Music Festival is an advanced training institute operated by Kent State University in cooperation with The Cleveland Orchestra and Blossom Music Center. This summer intensive program presents public performances by distinguished artist faculty and talented young musicians. The festival is under the direction of Kent State faculty members and esteemed musicians Danna Sundet (oboe) and Keith Robinson (cello).
Celebrating its 45th year, this program, which has developed an international reputation, began in the hands of legendary figures George Szell, Aaron Copland, Louis Lane, William Steinberg, Rudolph Firkusny, Rafael Druian, Lynn Harrell, Maurice Sharp, John Mack, Robert Marcellus, Myron Bloom, and many others of equal reputation.
The program primarily draws college-age students who are eager to work with the highly-revered faculty made up of current members of The Cleveland Orchestra, faculty members from Kent State's Hugh A. Glauser School of Music and other acclaimed musicians. This year, nearly 150 audition tapes were submitted for the 43 available slots. These young artists travel from around the globe to participate in the yearly summer tradition to celebrate and perform great chamber music. Students develop professional skills through personal study and classes with visiting master artists, members of The Cleveland Orchestra and Kent State faculty. A focus on major works of the chamber music repertoire is augmented by studies in orchestral repertoire and techniques and solo master classes. Participants also attend open rehearsals and concerts of The Cleveland Orchestra.
"We have students traveling from as far as Taiwan and Japan, but also boast some of Northeast Ohio's best student musicians from the Cleveland Institute of Music, Oberlin and Kent State's School of Music," says co-director Sundet.
The festival culminates with the "side by side" concert where the students perform at the Blossom Music Center with The Cleveland Orchestra. This year, the concert takes place on July 28 at 8 p.m. A pre-concert at 7 p.m. features the Kent Blossom Chamber Orchestra and will be led by James Feddeck. For tickets to this concert, visit www.clevelandorchestra.com.
The public is invited to enjoy free concerts presented by the various student ensembles known as the Chamber Players' Concerts. These concerts provide the students an opportunity to perform in front of a live audience, and take place in Ludwig Recital Hall in the Music and Speech Building on 1325 Theatre Dr., on the Kent Campus. The Chamber Players' concerts are free and open to the public.
Series I
Friday, July 6, 7:30 p.m.
Saturday, July 7, 2:30 p.m.
Sunday, July 8, 2:30 p.m.
Series II
Friday, July 20, 7:30 p.m.
Saturday, July 21, 2:30 p.m.
Sunday, July 22, 2:30 p.m.
Sunday, July 22, 7:30 p.m.
The Kent/Blossom Music Festival also highlights its esteemed faculty members by offering a professional concert series known as the Faculty Concert Series, which includes five concerts, from June 27 to July 25, and features performances by high-profile musicians from The Cleveland Orchestra and faculty from the Kent State University Hugh A. Glauser School of Music. Almost all of the performers in the Faculty Concert Series serve as faculty for the 43 students attending the summer chamber music intensive.
All Faculty concerts take place in the Ludwig Recital Hall on the Kent Campus. Parking is free. General seating tickets are now available online. New this year are the five-concert and three-concert season subscriptions, which are currently available online at www.kent.edu/blossom. Special introductory pricing is $40 for the five-concert series (that is a $7 per ticket discount) and $33 (a $4 per ticket discount) for the three-concert series. Single tickets are also available online or at the door for $15 for adults, and $5 for students under 18 or with a valid college ID. Visa, MasterCard or Discover are accepted both online and at the door.
The following is the 2012 Faculty Series program schedule:
Wednesday, June 27
Magical Mozart!
Miami String Quartet with Jerry Wong performing Mozart Duo in B flat, Mozart String Quartet in G major and Mozart Piano Quartet in G minor
Monday, July 2
Passion, Personality and Energy!
Miami String Quartet with Jerry Wong performing Joan Tower "Incandescent," Mendelssohn Quartet in F minor and Brahms Piano Quintet in F minor
Wednesday, July 11
Romance and Rhapsodies
The Cleveland Orchestra Piano Trio and Friends:
Peter Otto, Richard Weiss, Joela Jones, Stan Konopka and Danna Sundet performing, Clara Schumann: Three Romances, Loeffler Two Rhapsodies and Brahms B Major Piano Trio
Wednesday, July 18
Luscious Evening of Music
Cellist Mark Kosower with Pianist Jee-Won Oh performing Berteau Sonata in G major, Beethoven Sonata in D major, Cassado Suite for Solo Cello and Brahms Sonata in F major
Wednesday, July 25
The Winds of the Cleveland Orchestra
Marisela Sager, Jeffrey Rathbun, Daniel McKelway, Barrick Stees and
Richard King performing works by Rathbun: Phases for Woodwind Quintet, Dring: Trio and locally acclaimed composer Griebling-Haigh.
For more information, visit www.kent.edu/blossom or call 330-672-2613.


text:
Finley Siamese Cat Plate (edged)
Here at Catnap we cater to seekers of the individual and fun! Our cat pattern designs are available on china plates, bowls and homeware! Everything is created in our small studio in London and our designs are unique to our brand. To be sure about quality we send our designs to Stoke-on-Trent where our products are finished by skilled craftspeople who mould, print, apply, glaze and fire each product lovingly by hand on responsibly sourced fine bone china. (See our production processes for more!)
Loved by Siamese cat owners and fans alike, "The Finley" is one of our first cat plate designs and always take centre stage in any table setting.
Our plates can also be hung! These look great in smaller spaces, as well as large, making them ideal for flats and apartments :)
(Wall plate hangers for all plate sizes are also available sold separately.)
PLEASE NOTE: We operate small batch production and colour-ways can vary per batch.
Please select the size you want to see the available colour-way in that size.
To buy a matching whole set please email directly to firstname.lastname@example.com and we will check our availability.
- Dishwasher & microwave safe.
- Hand painted design.
- English Fine bone china made in Stoke-on-Trent.
- This will earn you 90 - 190 loyalty points.

subset: commoncrawl


text:
Worldwide Event Entertainment Hire - Entertainment Booking Made Easy
Welcome to our Entertainment Hire Directory, helping you to book entertainment for your upcoming Wedding, Party or Celebration.
To find Wedding Entertainment, Christmas Party Entertainers, Corporate Entertainment, Childrens Entertainers or any other Entertainers for Hire, simply start a search or click our 'request a quote' button below! Watch this video to find out how to book entertainment direct.
How are we different?
Traditional entertainment agencies charge a booking commission...we don't!
You can book your ideal act or event service with no middle man. Even better, if you can't find what you're looking for in our entertainment directory, simply send us a request & we'll find it for you.
Need Inspiration on which Entertainment Hire is best?
Watch the video above to find out more. And if you need some inspiration or advice on how to hire entertainment when planning a wedding, children's party or corporate event, just see our free complete guides and blogs below.
Looking for Entertaining Ideas?
Wedding Entertainment Hire
Looking for highly entertaining, fun & memorable entertainment choices for your wedding drinks reception or evening reception entertainment?
Popular wedding entertainment ideas:
Wedding Bands, Wedding Magicians, Wedding DJs, Wedding Singers, Caricaturists, String Quartets, Photo Booth Hire & Harpists.
Corporate Event Entertainment Hire
Dazzle your clients with spectacular corporate event entertainment!
Popular corporate entertainment to book:
Function & Party Bands, Comedy Acts, Musicians, Close-up Magicians, Tribute Acts, Tribute Bands, Party DJs, String Quartets, Stage Illusionists, Photobooth Hire.
Christmas Party Entertainment
Add a touch of sparkle to your seasonal celebration with some wonderful, show-stopping entertainment. Our Complete Guide covers everything you need to know, from popular Christmas Party themes, to planning tips and advice.
Popular Christmas Entertainment Hire: Singers, Live Bands, DJs, Magicians, Comedians, Chocolate Fountains.
Be Inspired by Some Outstanding Talent for Hire
Party DJ
Male Singer
Opera Singer
Male Singer
Mentalist / Mind Reader
Elvis Impersonator
Cover Band
Acoustic Guitarist / Vocalist
Neil Diamond Tribute Act
Read These Blog Posts for More Entertainment Inspiration
Our Latest Members!
From: Chicago, Illinois
Comedy Singer
From: Boise City, Idaho
Elvis Impersonator
From: Orlando, Florida
Elvis Impersonator
From: Ellijay, Georgia
Elvis Impersonator
From: Riverdale, Georgia
Elvis Impersonator
From: Michigan
Multiple Tribute Act
From: Midlands
Stage Illusionist
From: Wolverhampton, West Midlands
Fire Performer
From: Dublin, Leinster
Photo Booth
From: Pennsylvania
Want us to send you inspiration for your Wedding, Kid's Party or Event?


text:
As one of the original firms, we've never lost sight of the fact that consulting is a people business. A global partnership in more than 40 countries, our people make us who we are. We're individuals with different passions and strengths who take as much joy in the work we do as from those we work with.
Our strategic operations heritage means we've always known that a plan is only as good as the outcome it inspires. In practice, our teams bring the perspective, understanding, and hands-on know-how to build the future as you see it. Working together we'll see big ideas through to working realities, helping you move from keeping up to breaking through.
Because we'd rather hear from you than talk any more about ourselves, we'll get to the point. Our promise is simple—to deliver the guidance you need to make real progress. Let's get going.


text:
The week he began work as a Harvard University fellow and was hired as a consultant for Edelman public relations, former Mayor Antonio Villaraigosa on Friday was named a part-time professor at the USC Price School of Public Policy.
In the position, which was effective last Monday, Villaraigosa will work on "innovative, large-scale approaches" to public policy in the state, officials said.
In his final days as mayor, Villaraigosa, a graduate of UCLA, said he wanted to explore issues related to ending some of the partisan gridlock that has gripped Sacramento and Washington, D.C.
Jack H. Knott, dean of the Price School, said it was Villaraigosa's track record in dealing with a myriad of issues, everything from unions and transportation to infrastructure and public safety.
"His wide range of knowledge and hands-on experience in these areas and others, including education and governance, will serve as a great asset to the USC Price School's ongoing work and research," Knott said.
Villaraigosa's title, professor of practice, is reserved for faculty appointments of individuals who have made significant contributions in the public practice of their area of expertise.
Villaraigosa noted he was looking forward to the challenge. "I am excited about working with the school to propose solutions to some of the state's and nation's critical policy challenges," he said.
The former mayor will be a principal in the newly formed USC Villaraigosa Initiative for Restoring the California Dream, designed to focus on governance, public-private partnerships and social innovation. He'll also lecture to graduate and undergraduate classes on public-sector management.
Since leaving office, Villaraigosa has taken on a number of new jobs. In addition to the Harvard and Edelman appointments, he was named as an adviser to Banc of California, Herbalife and the Bipartisan Policy Center in Washington, D.C.


text:
Back in 2006, Paul Collins wrote an article in Slate asking "Will Google Book Search uncover long-buried literary crimes?" Now that we have large corpuses of texts searchable online, he argued, it will become much easier to find words lifted from other writers than it once was. (Collins reported on a few such cases found in early GBS searches.) The Net may make it easier for people to misappropriate other authors' words, but it also makes such misappropriation easier to detect.
Indeed, it's starting to finger some well-known contemporary authors. Last week, some bloggers used GBS to finger a prolific, and still publishing, romance author who was repeatedly plagiarizing the works of others. (The linked story is the first report of the news last Monday; its sidebar currently point to numerous followups, including more examples uncovered by the same blog and its readers.) Cassie Edwards may be one of the first well-known current authors to be caught out via online-library Googling, but she's not likely to be the last. Here are some things mentioned in the ensuing discussions that may be worth remembering the next time this sort of thing comes to light:
Plagiarism is not the same as copyright infringement and is therefore not justifiable with a "fair use" excuse. Plagiarism and infringment both involve improper copying, but otherwise they have important differences. Copyright infringement is copying without proper authorization (either from the copyright holder, or from copyright law), and is a legal offense. Plagiarism is copying without proper attribution, and is an ethical offense. While they sometimes go together, it's perfectly possible to plagiarize without violating copyright (such as by plagiarizing public domain sources), and violate copyright without plagiarizing (such as by putting the Harry Potter books on your web site, with J. K. Rowling's name left on them.)
Standards of proper attribution may vary by genre, but they exist for all genres. Formal scholarly writing standards are especially strict about attribution, with detailed citations generally required for words or even ideas taken from someone else. Popular fiction, music, preaching, and the like, may not usually include footnotes, and reuse may be more common in those genres (especially for things like standard chord progressions), but generally speaking, if you "quote" extensively from someone else, you're expected to credit them. This can be in your acknowledgements, your liner notes, or wherever, but if it's more than just a brief or obvious allusion (like the title of this post, taken from a Tom Lehrer song about plagiarism) you need to credit it.
Plagiarism may be forgivable, but not excused or justified, at least for anyone who expects professional respect. Being caught early on may ironically be a blessing; had Edwards been caught out by her editor or a reader on one of the first of her 100+ books, perhaps she could have apologized, changed her ways, and gone on to earn lasting plaudits on her original writing in the books that followed. For that matter, had Edwards' plagiarism been limited just to nonfiction "infodumps", and kept out of her story narratives, as it appeared in the first examples to be uncovered, it might have been easier to let go of. Unfortunately, it turns out she also lifted descriptive passages from fiction, which cuts closer to her main line of work as a storyteller.
On the other hand, I find it easier to forgive someone like Martin Luther King, who was (posthumously) found to have plagiarized in many of his academic writings, including his doctoral dissertation. Since Rev. King is best known and honored as a great civil rights leader, it's easier to forgive this flaw that it would be if he were mainly remembered as an academic or an author. But it's still sad, as it is when one uncovers the flaws of any of our American heroes (as you will for any of them, if you look closely enough). And now I can't hear someone call him "Doctor Martin Luther King" without mentally interpolating an asterisk after the title.
More than ever, now that people's words are increasingly available for searching and scanning in perpetuity, it's important to take responsibility for what goes out under your name, whether you're a storyteller, a scholar, or a politician. If you own up to your mistakes and sins early on, and do what you can to fix them, there may be good hope of redemption. Wait, and the damage can worsen both for those you've wronged and for yourself. I'll try to remember that in my own writing, and I hope my readers will help hold me to it.


text:
Department of Health and Human Services
National Institutes of Health (NIH), (http://www.nih.gov)
Components of Participating Organizations
National Heart, Lung and Blood Institute (NHLBI), (http://www.nhlbi.nih.gov)
Title: Translational Programs in Lung Diseases (P01)
Announcement Type
Looking ahead: As part of the Department of Health and Human Services' implementation of e-Government the NIH will gradually transition each research grant mechanism to electronic submission through Grants.gov and the use of the SF 424 Research and Related (R&R) forms. For more information and an initial timeline, seehttps://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-035.html. NIH will announce each grant mechanism change in the NIH Guide to Grants and Contracts (https://grants.nih.gov/grants/guide/index.html).
Program Announcement (PA) Number: PAR-09-185
Catalog of Federal Domestic Assistance Number(s)
Key Dates
Release Date: May 14, 2009
Letters of Intent Receipt Date(s): August 25, 2009; April 25, 2010; August 25, 2010; April 25, 2011; August 25, 2011; April 26, 2012; August 25, 2012
Application Submission Dates(s): September 25, 2009; May 25, 2010; September 25, 2010; May 25, 2011; September 25, 2011; May 26, 2012; September 25, 2012
Peer Review Date(s): February/March 2010; October/November 2010; February/March 2011; October/November 2011; February/March 2012; February/March 2012; October/November 2012; February/March 2013
Council Review Date(s): May 2010, January 2011, May 2011, January 2012, May 2012, January 2013, May 2013
Earliest Anticipated Start Date: July 2010, April 2011, July 2011, April 2012, July 2012, April 2013, July 2013
Additional Information To Be Available Date (Url Activation Date): TBD
Expiration Date: September 26, 2012
Due Dates for E.O.
Not Applicable
Additional Overview Content
Executive Summary
Table of Contents
Part I
Overview Information
Part II Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
Section II. Award Information
1. Mechanism of Support
2. Funds Available
Section III. Eligibility Information
1. Eligible Applicants
A. Eligible Institutions
B. Eligible Individuals
2. Cost Sharing or Matching
3. Other - Special Eligibility Criteria
IV. Application and Submission Information
1. Address to Request Application Information
2. Content and Form of Application Submission
3. Submission Dates and Times
A. Receipt and Review and Anticipated Start Dates
1. Letter of Intent
B. Sending an Application to the NIH
C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements
V. Application Review Information
1. Criteria
2. Review and Selection Process
A. Additional Review Criteria
B. Additional Review Considerations
C. Resource Sharing Plan(s)
3. Anticipated Announcement and Award Dates
Section VI. Award Administration Information
1. Award Notices
2. Administrative and National Policy Requirements
3. Reporting
Section VII. Agency Contact(s)
1. Scientific/Research Contact(s)
2. Peer Review Contact(s)
3. Financial/ Grants Management Contact(s)
Section VIII. Other Information - Required Federal Citations
Part II - Full Text of Announcement
Section I. Funding Opportunity Description
Research Objectives
During the latter part of the 20th century, basic biomedical research advanced rapidly with the advent of new technologies that made it possible to examine biology at the molecular level in an unprecedented manner. Researchers have successfully "translated" some of these findings into the development of new therapies and treatment strategies that are based on knowledge of disease process, reduce morbidity, and, in some cases, significantly prolong survival. Examples include: basic research on the immunopathology of asthma that has led to the development of immunomodulatory therapies, enhanced understanding of the air:liquid interface and microbial colonization of the lung in cystic fibrosis leading to more effective treatment of pulmonary infections and new insight into the pathogenesis of pulmonary hypertension leading to development of targeted therapies. However, for the most part, this wealth of new found knowledge has not been used to its full potential to improve prevention, diagnosis and treatment of pulmonary diseases. Translational research, defined as applying new knowledge and techniques generated by advances in basic research to application in the clinic to improve health, is not a straightforward process, and there are barriers to fulfilling the promise of translational research. Multidisciplinary approaches are needed that bring together basic and clinical researchers in an interactive effort to enable the transfer of new found insight from basic to clinical application.
The purpose of this P01 program is to encourage interdisciplinary approaches to lung translational research, allowing for potentially high-impact research, which will translate basic observations to applied clinical research. A P01 application to NHLBI requires a minimum of three interrelated research projects that focus a number of scientific disciplines on investigations of a complex biomedical theme or research question. Applicants will be required to propose research that will become progressively more clinical and translational during the life of the program project, and they are expected to assemble interactive, multidisciplinary teams that have the combined expertise to formulate a plan for successful translation. Research teams are not required to have prior collaborative experience but must be able to demonstrate an integrated, practical approach that will result in the effective progression of mechanistic/basic concepts toward application in the clinic. This program allows for a maximum of two 5-year awards (a new application and one competing renewal). The first 5-year grant cycle will require a clinical/translational research component (at least 25% of the total research proposed) as defined by the instructions in the PHS 398 for human subjects (http://grants1.nih.gov/grants/funding/phs398/phs398.pdf) that will test the potential of basic research observations for evolution into clinical application for the prevention, diagnosis or treatment of lung and sleep diseases. In the second grant cycle, applicants from the first cycle will further develop their project into a program with a significant clinical/translational research component (at least 50% of the total research proposed). Applicants that have a mature translational program may apply directly for the second cycle. These latter types of applications are eligible for only one cycle of this program.
Each new and renewal application should include a translation plan that discusses how expected results will specifically inform the development of new diagnostic, prognostic or therapeutic strategies for lung and/or sleep diseases. The applicant must discuss the ultimate goal of the particular research program: the development and application of a specific product or deliverable (e.g., small molecules, biologics, methodologies to be used in the prevention, diagnosis or treatment of lung and/or sleep diseases) and outline a progression for achieving this goal. It is not expected that all basic concepts will translate into direct clinical application within the two 5-year cycles. However, promising initial findings, the intent to translate, the type of application envisioned and a stepwise plan for progression must be described. If appropriate, a discussion of anticipated interactions with federal regulatory agencies or other partners should be included.
Applications that address basic mechanistic questions of disease pathology without identification of a specific translational milestone(s) or without a plan for reaching that milestone(s) are not appropriate for this FOA and will not fulfill the goals of this FOA.
Examples of research objectives that are encouraged through this program might include, but are not limited to, the following:
See Section VIII, Other Information - Required Federal Citations, for policies related to this announcement.
1. Mechanism of Support
This funding opportunity announcement (FOA) will use the Program Project Grant (P01) award mechanism. The applicant will be solely responsible for planning, directing, and executing the proposed project.
This FOA uses "Just-in-Time" information concepts. It also uses non-modular budget formats described in the PHS 398 application instructions (see https://grants.nih.gov/grants/funding/phs398/phs398.html).
U.S. applicants requesting more than
$250,000 in annual direct costs must complete and submit budget requests using
the Research & Related Budget component.
2. Funds Available
the nature and scope of the proposed research will vary from application to
application, it is anticipated that the size of each award will also vary.
Although the financial plans of the IC(s) provide support for this program,
awards pursuant to this funding opportunity are contingent upon the availability
of funds.
Facilities and administrative costs requested by consortium participants are not included in the direct cost limitation, see NOT-OD-05-004.
grants policies as described in the NIH
Grants Policy Statement.
3. Other-Special Eligibility Criteria
In order to fulfill the requirements of this FOA applicants must include:
Section IV. Application and Submission Information
1. Address to Request Application
The PHS 398 application instructions are available at https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive format. Applicants must use the currently approved version of the PHS 398. For further assistance contact GrantsInfo, Telephone (301) 710-0267, Email: email@example.com.
Telecommunications for the hearing impaired: TTY 301-451-5936.
2. Content and Form of Application Submission
Applications must be prepared using the most current PHS 398 research grant application instructions and forms. Applications must have a D&B Data Universal Numbering System (DUNS) number as the universal identifier when applying for Federal grants or cooperative agreements. The D&B number can be obtained by calling (866) 705-5711 or through the web site at http://www.dnb.com/us/. The D&B number should be entered on line 11 of the face page of the PHS 398 form.
The title and number of this funding opportunity must be typed in item (box) 2 only of the face page of the application form, and the YES box must be checked.
Additional information is available in the PHS 398 grant application instructions.
3. Submission Dates and Times
See Section IV.3.A. for details.
Submission, Review and Anticipated Start Dates
Letter of Intent Receipt Date(s): August 25, 2009; April 25, 2010; August 25, 2010; April 25, 2011; August 25, 2011; April 26, 2012; August 25, 2012
Application Receipt Date(s): September 25, 2009; May 25, 2010; September 25, 2010; May 25, 2011; September 25, 2011; May 26, 2012; September 25, 2012
Peer Review Date(s): February/March 2010; October/November 2010; February/March 2011; October/November 2011; February/March 2012; February/March 2012; October/November 2012; February/March 2013
Council Review Date(s): May 2010, January 2011, May 2011, January 2012, May 2012, January 2013, May 2013
Earliest Anticipated Start Date(s): July 2010, April 2011, July 2011, April 2012, July 2012, April 2013, July 2013
3.A.1. Letter of Intent
Prospective applicants are asked to submit a letter of intent that includes the following information:
Although a letter of
intent is not required, is not binding, and does not enter into the review of a
subsequent application, the information that it contains allows IC staff to
estimate the potential review workload and plan the review.
The letter of intent is to be sent by the date listed in Section IV.3.A.
The letter of intent should be sent to:
Chief, Review Branch
Division of Extramural Research Activities
National Heart, Lung, and Blood Institute
Rockledge 2, Room 7214
6701 Rockledge Drive, MSC 7924
Bethesda, MD 20892-7924 (Express zip: 20817)
Telephone: (301) 435-0270
Fax: (301) 480-0730
Email: firstname.lastname@example.com
3.B. Sending an Application to the NIH
must be prepared using the research grant application forms found in the PHS
398 instructions for preparing a research grant application. Submit a signed,
typewritten original of the application, including the checklist, and three
signed photocopies in one package to:
Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710 (U.S. Postal Service Express or regular mail)
Bethesda, MD 20817 (for express/courier service; non-USPS service)
Personal deliveries of applications are no longer permitted (see https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-040.html).
the time of submission, two additional copies of the application and all copies
of the appendix materials must be sent to:
Chief, Review Branch
Division of Extramural Research Activities
National Heart, Lung, and Blood Institute
6701 Rockledge Drive
Room 7214, MSC 7924
Bethesda, MD 20892-7924 (Express zip: 20817)
Telephone: (301) 435-0270
Email: email@example.com
3.C. Application Processing
Applications must be submitted on or before the application
receipt/submission dates described above (Section
IV.3.A.) and at https://grants.nih.gov/grants/dates.htm.
Upon receipt applications will be evaluated for completeness by CSR. Incomplete applications will not be reviewed.
The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial merit review unless the applicant withdraws the pending application. The NIH will not accept any application that is essentially the same as one already reviewed. However, the NIH will accept a resubmission application, but such application must include an Introduction addressing the critique from the previous review.
Information on the status of an application should be checked by the Principal Investigator in the eRA Commons at: https://commons.era.nih.gov/commons/.
4. Intergovernmental Review
This initiative is not subject to intergovernmental review.
5. Funding Restrictions
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable. A grantee may, at its own risk and without NIH prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new or renewal award if such costs: (1) are necessary to conduct the project; and (2) would be allowable under the grant, if awarded, without NIH prior approval. If specific expenditures would otherwise require prior approval, the grantee must obtain NIH approval before incurring the cost. NIH prior approval is required for any costs to be incurred more than 90 days before the beginning date of the initial budget period of a new or renewal award.
The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred. NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project (see NIH Grants Policy Statement https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm.)
6. Other Submission Requirements
This funding opportunity announcement (FOA) will use the Program Project Grant (P01) award mechanism. The applicant will be solely responsible for planning, directing, and executing the proposed project.
Qualifications and Experience: The qualifications and experience of the PIs to carry out translational research in a collaborative and multidisciplinary manner should be described in narrative in the appropriate sections and in biosketches.
Research Strategy Page Limitations
The page limit for each Research Strategy section is 12 pages for projects and 6 pages for cores. The page limit for the Overall Research Strategy is 12 pages. See http://www.nhlbi.nih.gov/funding/policies/ppg.htm for instructions.
Instructions for Applications Requesting $500,000 (direct costs) or More per
Applicants requesting $500,000 or more in direct costs for any year (excluding consortium F&A costs) must carry out the following steps:
1) Contact the IC program staff at least 6 weeks before submitting the application, i.e., as plans are being developed for the study;
2) Obtain agreement from the IC staff that the IC will
accept the application for consideration for award; and,
3) Include a cover letter with the application that identifies the staff member and IC who agreed to accept assignment of the application.
This policy applies to all new, renewal, revision, or resubmission applications. See NOT-OD-02-004, October 16, 2001.
Applicants must adhere to NHLBI guidelines for submission of PPG applications (http://www.nhlbi.nih.gov/funding/policies/ppg.htm).
Standard PPG
NHLBI approval
required for submission over $500,000
Multi-disciplinary team
Not required
Prior collaboration among team members
Not required
Clinical research
Not required
Translation Plan
Not required
Projects & Core(s)
Projects & Core(s)
$1,515 million direct costs per year, maximum
Cycle I: $1.75 million direct costs per year, maximum
Cycle II: $2.0 million direct costs per year, maximum
Not limited
2 grant cycles (10 years max.)
Review Criteria
Standard plus translation plan
Appendix Materials
All paper PHS 398 applications submitted must provide appendix material on CDs only. Include five identical CDs in the same package with the application. See https://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-031.html.
Do not use the Appendix to circumvent the page limitations. An application that does not observe the required page limitations may be delayed in the review process.
Resource Sharing Plan(s)
NIH considers the sharing of unique research resources developed through NIH-sponsored research an important means to enhance the value of, and advance, research. When resources have been developed with NIH funds and the associated research findings published or provided to NIH, it is important that they be made readily available for research purposes to qualified individuals within the scientific community. If the final data/resources are not amenable to sharing, this must be explained in Resource Sharing section of the application. See https://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm.
(a) Data Sharing Plan: Investigators seeking $500,000 or more in direct costs in any year are expected to include a brief 1-paragraph description of how final research data will be shared, or explain why data-sharing is not possible. Applicants are encouraged to discuss data-sharing plans with their NIH program contact. See Data-Sharing Policy or https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html.
(b) Sharing Model Organisms: Regardless of the amount requested, all applications where the development of model organisms is anticipated are expected to include a description of a specific plan for sharing and distributing unique model organisms and related resources, or state appropriate reasons why such sharing is restricted or not possible. See Sharing Model Organisms Policy, and NIH Guide NOT-OD-04-042.
(c) Genome-Wide Association Studies (GWAS): Regardless of the amount requested, applicants seeking funding for a genome-wide association study are expected to provide a plan for submission of GWAS data to the NIH-designated GWAS data repository, or provide an appropriate explanation why submission to the repository is not possible. A genome-wide association study is defined as any study of genetic variation across the entire genome that is designed to identify genetic associations with observable traits (such as blood pressure or weight) or the presence or absence of a disease or condition. For further information see Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies, NIH Guide NOT-OD-07-088, and https://grants.nih.gov/grants/gwas/.
Section V. Application Review Information
Only the review criteria described below will be considered in the review process.
Review and Selection Process
Applications submitted for this funding opportunity will be assigned on the basis of established PHS referral guidelines to the ICs for funding consideration.
Applications that are complete will be evaluated for scientific and technical merit by an appropriate special emphasis peer review group convened by NHLBI and in accordance with NIH peer review procedures (http://grants1.nih.gov/grants/peer/), using the review criteria stated below.
As part of the scientific peer review, all applications will:
Applications submitted in response to this funding opportunity will compete for available funds with all other recommended applications. The following will be considered in making funding decisions:
The mission of the NIH is to support science in pursuit of knowledge about the biology and behavior of living systems and to apply that knowledge to extend healthy life and reduce the burdens of illness and disability. As part of this mission, applications submitted to the NIH for grants or cooperative agreements to support biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
Overall Impact. All reviewers will provide an overall impact/priority score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following five core review criteria, and additional review criteria (as applicable for the project proposed).
Core Review Criteria. Assigned reviewers will consider each of the five review criteria below in the determination of scientific and technical merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance. Does the project address an important problem or a critical barrier to progress in the field? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
Investigator(s). Are the PD/PIs, collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation. Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach. Are the overall strategy, methodology, and analyses well-reasoned
and appropriate to accomplish the specific aims of the project? Are
potential problems, alternative strategies, and benchmarks for success
presented? If the project is in the early stages of development,
will the strategy establish feasibility and will particularly risky aspects be
If the project involves clinical research, are the plans for (1) Protections for Human Subjects, and (2) inclusion of minorities and members of both sexes/genders, as well as the inclusion of children, justified in terms of the scientific goals and research strategy proposed?
Environment. Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
In addition to the above review criteria, the following criterion will be applied to applications in the determination of scientific merit and the impact/priority score.
Translation Plan: Will the results promote or enable the clinical application of basic scientific research? Is a specific deliverable described? Is there a plan that effectively describes the expected evolution of the proposed research to application in the clinical or public health arena? Is the expected translation of research results feasible? Are anticipated interactions with regulatory agencies and/or other partners discussed, if appropriate? What is the potential impact on disease burden in terms of public health?
Additional Review Criteria
As applicable for the project proposed, reviewers will consider the following additional items in the determination of scientific and technical merit, but will not give separate scores for these items.
Protections for Human Subjects. For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials.
Inclusion of Women, Minorities, and Children. When the proposed project involves clinical research, the committee will evaluate the proposed plans for inclusion of minorities and members of both genders, as well as the inclusion of children.
Vertebrate Animals. The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following five points: 1) proposed use of the animals, and species, strains, ages, sex, and numbers to be used; 2) justifications for the use of animals and for the appropriateness of the species and numbers proposed; 3) adequacy of veterinary care; 4) procedures for limiting discomfort, distress, pain and injury to that which is unavoidable in the conduct of scientifically sound research including the use of analgesic, anesthetic, and tranquilizing drugs and/or comfortable restraining devices; and 5) methods of euthanasia and reason for selection if not consistent with the AVMA Guidelines on Euthanasia.
Resubmission Applications. When reviewing a Resubmission application (formerly called an amended application), the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewal Applications. When reviewing a Renewal application (formerly called a competing continuation application), the committee will consider the progress made in the last funding period.
Revision Applications. When reviewing a Revision application (formerly called a competing supplement application), the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
Biohazards. Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Additional Review Considerations
As applicable for the project proposed, reviewers will address each of the following items, but will not give scores for these items and should not consider them in providing an overall impact score.
Budget and Period Support. Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Select Agents Research. Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Applications from Foreign Organizations. Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Resource Sharing Plans. Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm); 2) Sharing Model Organisms (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-04-042.html); and 3) Genome Wide Association Studies (GWAS) (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-088.html).
Section VI. Award Administration Information
1. Award Notices
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant. For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General.
Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See Also Section IV.5. Funding Restrictions.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the grants management officer is the authorizing document. Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official (designated in item 12 on the Application Face Page). If a grantee is not email enabled, a hard copy of the NoA will be mailed to the business official.
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General (https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm) and Part II Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities (https://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm).
3. Reporting
When multiple years are involved, awardees will be required to submit the Non-Competing Continuation Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.
A final progress report, invention statement, and Financial Status Report are required when an award is relinquished when a recipient changes institutions or when an award is terminated.
We encourage
your inquiries concerning this funding opportunity and welcome the opportunity
to answer questions from potential applicants. Inquiries may fall into three
areas: scientific/research, peer review, and financial or grants management
1. Scientific/Research Contacts:
Patricia Noel, Ph.D.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
6701 Rockledge Drive
Bethesda, MD 20892-7952
Telephone: (301) 435-0202
Email: email@example.com
2. Peer Review Contacts:
Chief, Review Branch
Division of Extramural Research Activities
National Heart, Lung, and Blood Institute
6701 Rockledge Drive
Room 7214, MSC 7924
Bethesda, MD 20892-7924 (Express zip: 20817)
Telephone: (301) 435-0270
Email: email@example.com
3. Financial or Grants Management Contacts:
Ms. Ryan Lombardi
Division of Extramural Research Activities
National Heart, Lung, and Blood Institute
Room 7154, MSC 7926
6701 Rockledge Drive
Bethesda, MD 20892-7926
Telephone: (301) 435-0144
Email: email@example.com
Section VIII. Other Information
Required Federal Citations
Vertebrate Animals:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (https://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (https://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.
Human Subjects Protection:
Federal regulations (45CFR46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (Phase I); efficacy studies (Phase II); efficacy, effectiveness and comparative trials (Phase III). Monitoring should be commensurate with risk. The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (NIH Policy for Data and Safety Monitoring, NIH Guide for Grants and Contracts, https://grants.nih.gov/grants/guide/notice-files/not98-084.html).
Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (https://grants.nih.gov/grants/policy/data_sharing).
Investigators should seek guidance from their institutions, on issues related to institutional policies and local IRB rules, as well as local, state and federal laws and regulations, including the Privacy Rule. Reviewers will consider the data sharing plan but will not factor the plan into the determination of the scientific merit or the impact/priority score.
Policy for Genome-Wide
Association Studies (GWAS):
NIH is interested in advancing genome-wide association studies (GWAS) to identify common genetic factors that influence health and disease through a centralized GWAS data repository. For the purposes of this policy, a genome-wide association study is defined as any study of genetic variation across the entire human genome that is designed to identify genetic associations with observable traits (such as blood pressure or weight), or the presence or absence of a disease or condition. All applications, regardless of the amount requested, proposing a genome-wide association study are expected to provide a plan for submission of GWAS data to the NIH-designated GWAS data repository, or provide an appropriate explanation why submission to the repository is not possible. Data repository management (submission and access) is governed by the Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies, NIH Guide NOT-OD-07-088. For additional information, see https://grants.nih.gov/grants/gwas/
Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see https://grants.nih.gov/grants/policy/model_organism/index.htm). At the same time the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh Dole Act (see the NIH Grants Policy Statement https://grants.nih.gov/archive/archive/grants/policy/nihgps_2003/index.htm). All investigators submitting an NIH application or contract proposal, beginning with the October 1, 2004, receipt date, are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible. This will permit other researchers to benefit from the resources developed with public funding. The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.
Access to Research Data through the Freedom of
Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide access to research data through the Freedom of Information Act (FOIA) under some circumstances. Data that are (1) first produced in a project that is supported in whole or in part with Federal funds and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA. It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm. Applicants may wish to place data collected under this funding opportunity in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time. If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application. In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.
Inclusion of Women, Minorities, and Children:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the new PHS Form 398; and updated roles and responsibilities of NIH staff and the extramural community. The policy continues to require for all NIH-defined Phase III clinical trials that: (1) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and (2) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.
Inclusion of Children as Participants in Clinical
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (https://grants.nih.gov/grants/funding/children/children.htm).
Required Education on the Protection of Human Subject
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel. The policy is available at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-116.html. Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov/). It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research.
Public Access Policy Requirement:
In accordance with the NIH Public Access Policy (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-033.html), investigators must submit or have submitted for them their final, peer-reviewed manuscripts that arise from NIH funds and are accepted for publication as of April 7, 2008 to PubMed Central (http://www.pubmedcentral.nih.gov/), to be made publicly available no later than 12 months after publication. As of May 27, 2008, investigators must include the PubMed Central reference number when citing an article in NIH applications, proposals, and progress reports that fall under the policy, and was authored or co-authored by the investigator or arose from the investigator's NIH award. For more information, see the Public Access webpage at http://publicaccess.nih.gov/.
Standards for Privacy of Individually Identifiable
Health Information:
The Department of Health and Human Services (DHHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information," the "Privacy Rule," on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the DHHS Office for Civil Rights (OCR).
Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution. The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?" Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at https://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.
URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations. For publications listed in the appendix and/or Progress report, internet addresses (URLs) must be used for publicly accessible on-line journal articles. Unless otherwise specified in this solicitation, Internet addresses (URLs) should not be used to provide any other information necessary for the review because reviewers are under no obligation to view the Internet sites. Furthermore, we caution reviewers that their anonymity may be compromised when they directly access an Internet site.
Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas. This FOA is related to one or more of the priority areas. Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372. Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The NIH Grants Policy Statement can be found at https://grants.nih.gov/grants/policy/policy.htm.
The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas. The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt. Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged. The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50% of their time (at least 20 hours per week based on a 40-hour week) for two years to the research. For further information, please see: http://www.lrp.nih.gov/.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health®
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.


text:
Skip to content
Jayo Felony
X.O. Wit Me
Jayo Felony
X.O. Wit Me
[Intro: Cold 187Um]
This is an escalation, merging every corner of your mind
I'm with the twist of a rhyme, we outlast time
We got KM.G in the house
DJ K-Oss in the house
Jayo Felony in the house
I must spit
[Verse 1: Cold 187Um]
Welcome to the tilt that the Tru's built
We on gold whips, with them killer lifts
Look here, tre swinging rag-top
Boy you didn't know we was some legends like Sasquatch?
Dot your I's, cross your T's, when you see these G's
We stand tall like them California palm trees
And everything is fine, when I roll
Cause I flips never slips sipping X.O...
[Verse 2: Km.G]
I X.O. before I sex-o, a Pimp Clinic ritual
Chips for the stacking, hoes wanna know what's cracking
I'm in, tell them they ain't coming through with that love potion
Ask me what I'm quoting, wondering, what I'm smoking
The bomb, more scarier than that shit her-on
Sweat out your bitch 'do fresh from the salon
I can't give it up, I love my leather and chrome
And my 20 inch rims, grin n***a, I'm gone yeah.....
[Hook: Cold 187Um and Km.G]
So now we got you hooked on X.O
So high the homegirls can't let go
See the homies still fading that X.O
Worldwide, Above The Law getting faded on another level
So now we got you hooked on X.O
So high the homeboys can't let go
See the homies still fading that X.O
What "X.O."
What "X.O."
[Verse 3: Jayo Felony]
Like I was born to be homicidal, so I let my black Glock spit
Motherfuckers don't wanna see this California shit
Who you can't go the mile so you ganked my penitentiary style
That I kicked since a juvenile
N***as who be foul get touched
Kicking this shit with Km.G and Hutch
Then I roll through your hood and blast such and such
More than your whole click with what I'm holding
Patrolling the block I'm from
If one gun aiming up, then 40 Glock'll come
Rock your son then I pop you one
Ugh, you done, kill a bitch in the sun
I ain't the one mothafucker
Like walking across a tiger, in a pork chop bikini n***a
You gon' get ate up, so you don't wan' see me
It'll be me in the chucks so if I steps in a three piece
It's D-O-G-C and he'll see deceased
I hold more alcohol than a liquor store
For sure, clown these hoes at a show
And for sure we X.O....
[Verse 4: Km.G]
Oh for sheezy n***a, I stay Eazy like E
I got hoes making sounds like Master P "Ugh"
I got homies with the bomb and we still on the run
Yeah, hooker hit the grind and it's tossing time
See I asked me homey Jayo what's the price on the yayo
Yeah right, they next to Mexico, the homey from Diego
Get the plug on the drop, hop
Then my n***as hit the club
Bring five of them back to kick it in the hot-tub..
[Verse 5: Cold 187Um]
We got the hook up from here to Okinawe
New and improved like the C-4 Volvo "yeah, yeah"
And remember one thing when you in my zone
Is that I still break a bitch conversating on a chipped phone
Cause I'm amazing like the great Houdini "ooohh weee"
And I be fly like that hit of ya Remi
Who wanna be me
I wanna see me when I'm on the grind
Cause I be straight hitting corners, X.O.'ing in the sunshine...
[Refrain: X6]
Km.G: See I can't lose, with the shit that I use
187Um: So everybody, X.O. Wit Me
[Outro: Street Dialogue]
Goddizamn, who's that knockin down the blizock like that homies
Oh that's the homies K-Oss, Hutch, Km.G
What's up my n***as, what's up man
What's up homey, trip, trip, trip (*Car Parked*)
Damn I'm trying to come up on some weed for the party
Oh they got you down the street
Where at?
Lafayette, got some bomb
Lafayette down the street
Not the Lafayette that I got into it at the club last week?
They got that pure
AIght Imma holla at them and see whats up
Come back if you dont get right


text:
Biochemistry and Molecular Biology
Academic Catalog: 2017–2018
- Jeffrey Dahlseid, Program Director
- Heather Haemig
- Brenda Kelly (Provost and Dean of the Faculty, 2017–2018)
- James Parejko (Visiting, 2017–2018)
Biochemistry and Molecular Biology is the study of the structures and functions of biological molecules. It entails investigating macromolecules such as proteins, nucleic acids, carbohydrates, and lipids in order to understand their functions and interactions with each other, with small molecules, and with their surroundings. In essence, it is the study of the molecular basis of life.
The interdisciplinary Biochemistry and Molecular Biology major at Gustavus is intended for students interested in areas close to the interface between chemistry and biology, such as bioinformatics, biophysics, biotechnology, genetics, neuroscience, and pharmacology, and provides a superb preparation for graduate or professional study. The curriculum is designed to be rigorous and thorough with a solid foundation of science courses, a breadth of upper-level core courses in Chemistry, Biology, and Biochemistry, a research-like investigative laboratory curriculum, a capstone experience that includes vocational reflection, writing intensive courses, and a seminar program. Students pursuing graduate study are advised to engage in research and to consult their advisor about the elective courses most appropriate for their interests.
The distributive major in Biochemistry and Molecular Biology requires the following 16.5 courses:
- BIO-101, Principles of Biology; BIO-102, Organismal Biology; BIO-201, Cell and Molecular Biology
- CHE-107, Principles of Chemistry; CHE-141 and CHE-251, Organic I & II.
- MCS-121 and MCS-122, Calculus I & II. PHY-122 and PHY-172, General Physics I & II with Calculus.
- BIO-388, Molecular Genetics.
- CHE-255, Biochemistry and the capstone course, CHE-360, Proteins.
- CHE-371, Kinetics and Thermodynamics.
- BIO-202, Evolution, Ecology, and Behavior and an additional Level III biology course.
- Two chemistry courses, chosen from CHE-246, Environmental Chemistry; CHE-258, Inorganic I; CHE-270, Quantitative Analysis; and the Level III
chemistry courses.
Note: All majors must participate in four semesters of seminar (CHE-399).


text:
Material: Wood
Finish: Neutral
Need more than the in-stock quantity? Please allow a 6-10 week lead time for additional inventory.
Dimensions: 60.00"W x 60.00"D x 30.00"H
Mayker works with the best manufacturers to ensure that the design details, quality, safety, and sustainability of our products meet, if not exceed, your expectations. For information on returns, view our Return Policy.
We charge a flat-rate delivery fee on all purchases for shipments within the contiguous United States. For in-stock products, you can expect to receive your purchase within 3-5 weeks. For shipping and delivery details, view our Shipping Policy.


text:
So I have been tagged by my sister April Laramey in the Virtual Christmas Cookie Exchange. So I bring you the following recipe:
- 1 cup(s) Sugar
- 1/2 cup(s) Butter – Softened
- 1/2 cup(s) Shortening
- 3 1/2 tablespoon(s) Cream Cheese – Softened
- 1/2 teaspoon(s) Salt
- 1 whole(s) Egg
- 1/2 teaspoon(s) Almond Extract
- 2 cup(s) All Purpose Flour
- Food Coloring (As many different colors as you want the cookies to be!)
- Decorations
- Silver Candy Balls (If Desired)
- Food Sprinkles (If Desired)
- Sparkle Gel
- Edible Glitter
1. Combine butter, shortening and cream cheese in a large bowl, beat together until smooth. Add sugar and salt. Beat until combined. Beat in egg and almond extract until combined and gradually add the flour beating until combined.2. Form dough into a ball with your hands and then into a log shape, divide the log shape into six portions (or how ever many colors you want).
3. Place each portion of dough into individual wraps of plastic and tint the dough different colors (See Below for instructions on how to tint the dough)
4. Chill tinted dough in the refrigerator 1 hour or freezer 15-20 minutes.
5. Divide each tinted chilled dough ball into 8 equal pieces.
6. Take one piece of each colored dough (leaving the rest in the fridge while you work) and roll out like a rope or snake on your counter-top. If you use a piece of waxed paper on the counter, you shouldn't have to add any flour.
7. Roll the rope shape to about 6 inches long. Continue rolling all the colors and stacking them into a pile. Gently press the ropes together and roll the large multicolored "rope" on the counter to round and smooth it and if desired to lengthen it to 10 to 12″.
8. Cut the multicolored "rope" into two pieces, using both hands, roll with your palms in different directions on both end of the rope pieces to twist it gently.
9. Coil the rope into a poop shape, using your imagination as to what you think unicorn poop should look like
10. Press in some silver candy balls (dragee) into the dough pieces to decorate if desired. Place dough on greased cookie sheet (or one covered with parchment or silicone mat) and bake at 375 F for 8-10 minutes until cookies are set and bottoms are light brown, they will not spread very much.
11. Cool on wire rack.
12. Coat with sparkle gel and/or edible glitter to give them some sparkle and add some sprinkles to the still wet gel for more texture. Let cookies dry completely before stacking.
Dough Coloring Tint
Do this prior to chilling the dough, so that you don't undo the chilling process with your body heat.
1. Get a large piece of plastic wrap (to protect your hands and table from the dye), place a ball of cookie dough in the middle.
2. Poke a well in the center with your thumb.
3. Add the food coloring to the well and then fold the dough over the coloring.
4. Wrap it in the plastic wrap, and begin kneading the food coloring into your dough.
This may take a while and you may find that you need more food coloring (Hint: Colored Cookie Dough bakes lighter than what you see when you first tint the dough, once you've gotten the right color tint, add more).
I now tag Megan Chapman and dare her to find a better recipe!


text:
Spain d. Switzerland, 3-1.
What should have been one of the most amazing first round ties (worthy of a tournament final) turned out to be page 8 news when the world's no. 1 and 2 — Roger Federer and Rafael Nadal — pulled out. Nadal cited an injury (hip, I think), while Federer reasoned that his schedule would be too grueling with the addition of Davis Cup. So instead he spent his time in Dubai (his homebase) promoting a new five-blade men's razor. wtf. For a snappy dresser who's a wizard on the court, he can sure be a bore sometimes.
Ok, so now let's talk to the men that were actually there: Fernando Verdasco lost his first singles match against against Chiudinelli, but turned it around against Bohli on Sunday. I'm exccited for them! Spain lost in the first rounds in 2005 and 2006. Now they can set their sights on winning the Cup, like they did in 2004 (Remember Moya?). They face the U.S. in the next round, in the United States. We all know that this tie will not be played on clay.
Now, the clothing tie:
Spain's warm-ups are in very muted navy blue and white, without any hint of their loud yellow and red flag colors (-1):
That's Nadal and David Ferrer, above.
Below, Verdasco brings out some red (+1):
And while Ferrer isn't wearing country colors at all, he'll get some points for bringing the 70's back (+1). He's no Tommy Robredo in this department, but we'll give him a pat on the back for trying:
And Rafa: I'm sure you would have worn yellow (sleeveless shirt) and red (clamdiggers) proudly, so I'm sorry you missed this tie. Hopefully you'll have recovered by the time they play in April. You're likely the only Spaniard who can beat the red-hot Roddick right now.
The Swiss did alright with their outfits. They stuck to their country colors (+1), and both players looked good. Marco Chiudinelli (+1):
and Stephane Bohli (+1):
And Roger, you should know that I'm disappointed about your absence less because of the tennis with Nadal, and more because you would've likely added some spice to the Swiss team. You would have worn a cute headband. Or maybe you would've brought back that blazer you wore at Wimbledon). Will you be playing at all this year? You should.
In the future: I'd like to see the Swiss play with the cross in their flag as a pattern, and the Spaniards need to play with the lion in their seal. That can be emblazoned on the back of sweaters or jackets.
Spain: 2
Switzerland: 3
Switzerland wins.


text:
Jack Donaghy, a Bond Girl, a South African alien, a Pussycat Doll, and the reigning queen of internet memes all join the new Men in Black movie. Plus why Oz is the most Robert Downey, Jr. character ever. Spoiler alert!
Spider-Man Reboot:
Sony is offering no comment on whether the reports about Rhys Ifans playing the Lizard are true. If people want to make something of the fact that they only said no comment, not flat-out denied it, go right ahead, but I think those are precisely the sort of guessing games Sony wants in anticipation of naming the character in a little while. So I really wouldn't read much into their no comment either way, to be honest. [Hitflix]
Men in Black 3:
Alec Baldwin, Gemma Arterton, and Sharlto Copley are reportedly all in negotiations to join the cast. Alec Baldwin would play the 1960s head of the Men in Black, and Arterton his secretary, while Copley will play "a fast-talking Yoda type alien." It's unclear whether Copley would be a good guy, or the more humorous sidekick to Jemaine Clement's alien villain. I'll admit it - between this and the previous casting of Emma Thompson and Josh Brolin, this all sounds way more interesting than Men in Black 2. [/Film]
Depending on your tolerance level for internet memes, this will either be awesome news or just sorta irritating. Betty White — who, internet overexposure or not, is still a legendary comic actress and a welcome presence in pretty much anything — reportedly has a cameo playing one of the character's mothers. Also, Nicole Scherzinger of the Pussycat Dolls has reportedly been offered the role of Devil Girl, which I'm guessing is one of the villainous underlings of Clement's Yaz. [Bloody Disgusting]
Avatar 2:
James Cameron might take some time out before making the next Avatar movie to direct Angelina Jolie in a new Cleopatra movie. Knowing Cameron's working process, that could push Avatar 2 back five or so years. Which is all well and good, but here's the truly important question — what does this mean for Steven Soderbergh's "3-D live-action rock 'n' roll musical about Cleopatra" starring Hugh Jackman, Catherine Zeta-Jones, and the music of Guided by Voices? Inquiring minds want to know! [Deadline]
Star Trek 2:
Roberto Orci confirms that he and Alex Kurtzman have started writing the script. [Trek Movie]
There's another set report with a few more details on the movie. The Strause Brothers say the aliens are a scifi take on the Sirens of Greek mythology, and costar Brittney Daniel explains her character:
She's kind of like the self-absorbed, L.A. socialite girl," she said of her character. "And through the movie she starts to have a comeuppance. She starts to realize that the world doesn't revolve around her. She doesn't save the day, but she definitely takes part … in helping us get out when we need to get out [of the building] and kind of kick a little ass."
For more, including descriptions of some scenes, check out the link. [IGN]
This UK trailer is pretty much identical to the US one, except it has slightly better sound quality and no speaker pops. So...yay? [The Hollywood News]
Oz the Great and Powerful:
I didn't think this was possible, but this movie might just out-Downey the Iron Man films for pure Robert-Downey-Jr.-ness. The film reportedly stars the wizard - who will likely be played by Robert Downey Jr., but it hasn't been confirmed yet - as a fast-talking huckster whose libido constantly gets him into trouble, whether it's with angry husbands or jilted witches. The plot has Oz falling in love with Glinda the Good Witch, which causes Theodora the Morally Ambiguous Witch, whose advances he spurned, to team up with Evanora the Evil Witch to take him down. [Pajiba]
Mark Millar says that he's close to completing a couple potential deals to adapt Superior, his reasonably family-friendly tribute to golden age superheroes. (But take this with a grain of salt for now.) Millar says the two different groups he talked to mentioned the same actor for the lead role: Jon Hamm. That doesn't mean much apart from the fact that people recognize Jon Hamm would be great to play a Superman type, but the fact that Millar is already dropping that in may suggest they're going to very actively pursue Hamm for the role. So, for those hoping to see Hamm play the Man of Steel, this might be the project to watch - I'm guessing this is close as he's ever going to get, unfortunately. [Millar's World]
The Last Voyage of the Demeter:
This film, an adaptation of a section from Bram Stoker's Dracula in which the Count is transported to England on the ship the Demeter and the entire crew mysteriously dies in the crossing (hence the title), has reportedly added Ben Kingsley and Swedish Girl with the Dragon Tattoo star Noomi Rapace. Rapace, who is maybe the slightly better indicator this film could be worthwhile (Kingsley appears in a ton of dreck), is reportedly playing a stowaway on the ship. [The LA Times]
Uncharted - Drake's Fortune:
Nathan Fillion has started a Twitter campaign to get the lead role of Nathan Drake in the video game adaption. For those keeping track, if Malcolm Reynolds was Fillion's Han Solo, then this is his Indiana Jones. Of course, that makes Rick Castle Fillion's Rick Deckard - even their first names are the same! - but only because I think Castle would be a lot more entertaining if he spent his time killing replicants and hunting Rutger Hauer while being cryptically taunted by Edward James Olmos. [IGN]
There were reports yesterday that Guillermo del Toro had been offered the director's chair for a Godzilla reboot, but he denied it in the strongest possible terms - not only has no offer been made, he won't even read the script for such a movie. [Hitflix]
Transformers 3:
Here's a couple more photos of general Bayhem from the DC film shoot: [CinemaBlend]
We updated our report on this yesterday, but just in case people don't read Morning Spoilers multiple times over the course of a day (which you totally should, because you'll start picking up on the subtle metatextual layering I put into every post), the Bumblebee crash is not being written into the film, and Bay is just going to use his spare Bumblebee car. [TFW2005]
Harry Potter and the Deathly Hallows:
A couple more posters are out: [SpoilerTV]
Here's a pair of interviews with John Noble and Blair Brown: [SpoilerTV]
Elsewhere, Noble had some musings on what Walter will do now that he owns Massive Dynamic:
"He's had to reevaluate everything as he came out of that mist in his life. He has realized that the simplest thing, like the love of a parent for a child, is far more important than anything else. I'm not going to be the CEO of this business. He may think, 'I wonder what opportunities this gives me to do good science?' At the end of the day, I suppose something like Massive Dynamic could make a lot less profit and do a lot better science – if Walter has his say."
A bunch of promo photos are out for the next three episodes, "Amber 31422", "6955 kHZ", and "The Abducted". We've split them into three separate galleries: [<a href="">SpoilerTV]
[gallery 5664403]
Doctor Who:
The opening, Utah-set two-parter has reportedly added a few new characters. Peter Banks is reportedly playing Dr. Shepherd, Canadian actor Kerry Shale is playing a southerner (and we mean a US southerner, not someone from Point Pelee or something), and Kieran O'Connor is playing a guard. All of this thanks to our resident Doctor Who spoiler machine bluehinter!
The Event:
Here's a small sneak peek at the next episode, "Casualties of War": [SpoilerTV] Click to view
No Ordinary Family:
Here's a synopsis and some photos for the November 9 episode guest-starring Cybill Shepherd and Bruce McGill (D-Day from Animal House!) as Stephanie's parents: [KSiteTV]
When Stephanie's hard-to-please parents, Barbara (Cybill Shepherd) and Allan Crane, pay an unexpected visit, the Powells must curb the use of their powers for fear of giving away their secret. But Barbara and Allan begin to suspect that something's awry when they witness some strange behavior. Meanwhile, when friend Trent Stafford (Jackson Rathbone, the "Twilight" movies) and his parents are the victims of a home invasion, Daphne uses her abilities to help Jim try to track down the thugs responsible for the violent act.
This is as much a reflection of the general terribleness of this premiere season as anything else, but No Ordinary Family is pretty much ABC's only moderately successful new show, and it looks like it's sticking around - ABC has ordered four more scripts of the show, which means they will almost certainly order four more episodes too. It's the only new show ABC has done this for, so I'd give this show a decent chance of getting an entire season to figure its problems out. [KSiteTV]
Here's one more sneak peek for "Weekend at Bobby's": [SpoilerTV]
And now a few photos for episode 5, "Live Free or Twi Hard": [SpoilerTV]
Terra Nova:
This is quickly getting ridiculous. Steven Spielberg's time traveling dinosaur show hasn't even started shooting yet and the pilot reportedly already costs $10 million. Once it finally starts shooting, the final cost for the episode could be $20 million, making it the most expensive pilot in TV history, beating out Lost ($10-14 million) and Boardwalk Empire ($18 million). That's kind of a lot of money for a show starring the dude from the American Life on Mars and a British actress who's largely unknown in Britain, but we'll just have to wait and see, I guess. [TV Squad]
Being Human:
Here's an interview with Sam Witwer, in which he discusses the American remake (and his time playing Doomsday on Smallville): [SpoilerTV]
Click to view
Additional reporting by Katharine Trendacosta and Charlie Jane Anders.


text:
Abby: Veteran dad has no desire to start a second family
DEAR ABBY: I'm a single mom in a serious relationship with a divorced man who has children of his own. Between us, we have seven, ranging in age from 7 to 17. I'm in my early 30s; he's in his early 50s.
My dilemma: I'm interested in having another child if we get married. He definitely isn't.
Is it unreasonable for me to want to add to this already large potential blended family? I love the idea of experiencing motherhood again with a little more experience and age under my belt, and I'd love to share that intimacy with him.
While he likes the abstract possibility of "our" child, he says he feels too old now and he wouldn't be able to be the kind of father he would want to be.
If neither of us had kids of our own, this would be a deal-breaker for me, but how do I know if my maternal longings are just the last, painful tickings of my biological clock, or a real desire that I'll end up resenting him for if I ignore it and we stay together? - IS SEVEN ENOUGH?
DEAR IS SEVEN ENOUGH?: Because your boyfriend is in his 50s and has made it clear that he isn't interested in becoming a father again, I think you should count your many blessings and consider that seven is a lucky number.
DEAR ABBY: My godmother passed away in January 2011. My godfather, "Jim," remarried last year.
I am still mourning her loss and have not been able to get myself to call and speak to Jim, even though I did send him a congratulatory wedding card.
I love him. Jim is a wonderful, kind, attractive man. I knew it wouldn't be long before another woman would take an interest in him or he'd find love again. My siblings have tried to get me to make contact with him, but I'm still not ready to accept that he has moved on with another woman. Please advise me. - CAN'T FACE IT IN CALIFORNIA
DEAR CAN'T FACE IT: I am sorry for your loss, and I'm sure your godmother will always live in your heart.
However, if you love your godfather, you should be glad that he has been able to move forward in his life.
That he was open to finding love again speaks volumes about the quality of the marriage he shared with your godmother.
Of course seeing Jim with someone else won't be easy for you, but it is sad that you would sacrifice the special relationship you have with him because you are reluctant to face reality.
For both of your sakes, I hope you'll reconsider. If you do, you may find that you like the new lady in his life.
DEAR ABBY: Is it ever appropriate for a diner to lick his/her fingers in public, like when eating finger food or barbecue? It drives me nuts! I equate it to a cat cleaning itself.
When I try to get the person in question to use a napkin, I'm looked at as if I've lost my mind! At the very least, our hands are covered with germs, and who wants to stick them in their mouth? Yecch. - GROSSED OUT IN OHIO
DEAR GROSSED OUT: I think it depends upon the circumstances in which the food is being served. If someone is eating canapes at a cocktail party, licking the fingers is a no-no. And most barbecue joints provide moist towelettes to their patrons.
On the other hand, Col. Sanders used to call his fried chicken "finger lickin' good." At a picnic or informal gathering, it's purr-fectly acceptable to lick one's fingers, and I confess this tabby has probably done it, so I'm not going to cast aspersions.
Dear Abby is written by Abigail Van Buren, also known as Jeanne Phillips, and was founded by her mother, Pauline Phillips. Write Dear Abby at www.DearAbby.com or P.O. Box 69440, Los Angeles, CA 90069.
Good advice for everyone - teens to seniors - is in "The Anger in All of Us and How to Deal With It." To order, send your name and mailing address, plus check or money order for $7 (U.S. funds) to: Dear Abby, Anger Booklet, P.O. Box 447, Mount Morris, IL 61054-0447. (Shipping and handling are included in the price.)


text:
good chemistry is complicated,
and a little bit messy -LW
Learning from Obfuscationby flyingmoose (Priest)
|on Jan 23, 2004 at 14:37 UTC ( #323567=perlmeditation: print w/replies, xml )
|Need Help??
Perl Obfuscation is more of a game, per se, but perhaps there is something that can be learned from it. I'm stating this, simply enough, because I have yet to uncover any basic guides to the obfuscation techniques and/or thought processes employed on this forum.
I'd like to understand them. I can understand everyone's "regular" code, perfectly well, but I'm lost when it comes to reading "ugly" Perl code, pretty much because my brain doesn't want to overcome the pain threshold. I can see how writing some sort of interpreter would help in writing these obfuscations, but then the interpreter source is pretty darn obscure too, so that doesn't appear to be the route most folks take.
My question is this...would anyone like to provide a basic guide or a few short examples on obfuscation techniques, or otherwise unravel (section by section) a few sample obfuscations, or take some normal basic Hello World code and show a few obfuscations being applied? Possibly with a few contrasting techniques? I'm not doing this to enter the "obfuscation contests" on Perl Monks, I just think there is some really interesting/bizarre thought processes going on, and it's a shame if the obfuscations are posted without details.
Again, obfuscations have no value in commercial programs, in major projects, or even throwaway scripts...but I feel that I'm missing something essential without some basic ability to grok the evil dark corners of the Perl. I want to go there. Take me to the dark corners....
Also, random (and insane) question -- why isn't there any Lisp obfuscation? It seems writing an entire program out of nothing but parenthesis all on one line would have some EXCELLENT chances at giving us a run for our money. Sure, it would be longer, but probably even harder to grok.
Back to Meditations


text:
Hurricane Sandy poised to become 'megastorm'
Tropical storm warnings still in effect for Palm Beach Co., Treasure Coast
Tropical storm warnings for Palm Beach County and the Treasure Coast were still in effect late Friday as Hurricane Sandy continued on a northern course that WPBF 25 severe weather expert Mike Lyons says is poised to become a "megastorm" by the time it reaches the northeast as projected.
LIVE UPDATES: Get The Latest On Hurricane Sandy On WPBF.com
Tropical storm warnings continued for the waters of Palm Beach north of Deerfield Beach.
Hurricane Sandy continued to move northward away from South Florida.
Tropical storm conditions will continue over the Palm Beach waters overnight.
Maximum sustained winds were at 75 mph.
While the center of Hurricane Sandy will pass about 300 miles to the east of the area, there may be occasional tropical storm-force wind gusts through Saturday, particularly over the beaches.
Sandy is forecast to make landfall in the northeast by early next week.


text:
Most people know when to be afraid and when it's ok to calm down. But new research on autism shows that children with the diagnosis struggle to let go of old, outdated fears.
Even more significantly, the Brigham Young University study found that this rigid fearfulness is linked to the severity of classic symptoms of autism, such as repeated movements and resistance to change.
For parents and others who work with children diagnosed with autism, the new research highlights the need to help children make emotional transitions – particularly when dealing with their fears.
"People with autism likely don't experience or understand their world in the same way we do," said Mikle South, a psychology professor at BYU and lead author of the study. "Since they can't change the rules in their brain, and often don't know what to expect from their environment, we need to help them plan ahead for what to expect."
In their study, South and two of his undergraduate neuroscience students – Tiffani Newton and Paul Chamberlain – recruited 30 children diagnosed with autism and 29 without to participate in an experiment. After seeing a visual cue like a yellow card, the participants would feel a harmless but surprising puff of air under their chins.
Part-way through the experiment, the conditions changed so that a different color preceded the puff of air. The researchers measured participants' skin response to see if their nervous system noticed the switch and knew what was coming.
"Typical kids learn quickly to anticipate based on the new color instead of the old one," South said. "It takes a lot longer for children with autism to learn to make the change."
The amount of time it took to extinguish the original fear correlated with the severity of hallmark symptoms of autism. "We see a strong connection between anxiety and the repetitive behaviors," South said. "We're linking symptoms used to diagnose autism with emotion difficulties not usually considered as a classic symptom of autism."
The persistence of needless fears is detrimental to physical health. The elevated hormone levels that aid us in an actual fight or flight scenario will cause damage to the brain and the body if sustained over time. And the families who participate in social skills groups organized by South and his students can relate to the new findings.
"In talking to parents, we hear that living with classic symptoms of autism is one thing, but dealing with their children's worries all the time is the greater challenge," South said. "It may not be an entirely separate direction to study their anxiety because it now appears to be related."
REHACARE.de; Source: Brigham Young University


text:
Seafood Cornbread Dressing
This is a delicious entree...
Some of our favorite recipes...
Beignets – A French Doughnut
Beignet is Cajun French for "French Donut." Cafe Du Monde in New Orleans popularized this indulgent Cajun treat. See our complimentary blog post, Making Old-fashioned Beignets, for illustrated ...Read more
Cajun Deep Fried Turkey
One of my favorite cooking ideas is to deep fat fry our turkey for the holidays or New Year's parties. My wife loves it when I cook; gives ...Read more
What's Hot
Yummy Rice Dressing
This is one of our favorite rice dressing (also known as dirty rice) recipes. Add this to a meatball stew and talk about good! ...more
Boiled Crawfish
The crawfish boil is one the most popular Cajun meals. Cajun seafood boil seasonings (we love Slap Ya Mama's Seafood boil) do the trick ...more
Boudin Balls
We took a basic classic and made it better! IngredientsBoudin Crushed crackers 2 eggs (optional) 1/4 to 1/2 cup milk (optional) Salt, cayenne, black ...more
Rice and Gravy
Rice and gravy is a staple here in South Louisiana. It's one of the first things you learn to cook. Any meat can be ...more
Classic Boudin
This is the best classic boudin out there. Boudin is also spelled "boudoin." ...more
Couche Couche
This simple dish was once the everyday "supper" for Cajuns. Served with milk, figs or cane syrup....more
Boudreaux's Jambalaya
Jambalaya, a Cajun/Creole dish, is perhaps the most versatile main dish that Louisiana has to offer. ...more
Sweet Dough Tarts
This is a perfect dough for tarts. This dough doesn't have to be refrigerated for handling and can be prepared right away. ...more